President
Erin Kimbrel, PhD
Erin Kimbrel has over 25 years’ experience as a researcher and leader in multiple disciplines ranging from molecular cancer biology to regenerative medicine. She has served as Vice President of Research at AIRM since 2021, managing scientific teams involved in the development of hESC and iPSC-derived cell-based therapies in various therapeutic areas including ophthalmology, autoimmune and vascular diseases. Prior to that, she worked in small biotech, including serving as Senior Director of Development at Ocata Therapeutics and Director of Research at Advanced Cell Technology.
Dr. Kimbrel is a former Fulbright Scholar, receiving her B.A. Magna Cum Laude from Holy Cross College in Worcester, Massachusetts and her Ph.D. in Pharmacology and Cancer Biology from Duke University in Durham, North Carolina. She completed post-doctoral training in Boston, Massachusetts at the Dana-Farber Cancer Institute and Harvard Medical School with a focus on hematopoietic stem cell fate decisions. She is a co-author on over 25 publications and an inventor on numerous patents.